These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 33705845)

  • 1. Clinical impact and room for improvement of intensity and adherence to lipid lowering therapy: Five years of clinical follow-up from 164,565 post-myocardial infarction patients.
    Schiele F; Quignot N; Khachatryan A; Gusto G; Villa G; Kahangire D; Chauny JV; Ricci L; Desamericq G
    Int J Cardiol; 2021 Jun; 332():22-28. PubMed ID: 33705845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Treatment Intensity and Adherence to Lipid-Lowering Therapy with Major Adverse Cardiovascular Events Among Post-MI Patients in Germany.
    Ahrens I; Khachatryan A; Monga B; Dornstauder E; Sidelnikov E
    Adv Ther; 2021 May; 38(5):2532-2541. PubMed ID: 33830461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensity of and Adherence to Lipid-Lowering Therapy as Predictors of Major Adverse Cardiovascular Outcomes in Patients With Coronary Heart Disease.
    Mazhar F; Hjemdahl P; Clase CM; Johnell K; Jernberg T; Sjölander A; Carrero JJ
    J Am Heart Assoc; 2022 Jul; 11(14):e025813. PubMed ID: 35861825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of lipid-lowering treatment intensity and adherence on cardiovascular outcomes in patients with a recent myocardial infarction: a Swedish register-based study.
    Svensson MK; Sorio Vilela F; Leósdóttir M; Banefelt J; Lindh M; Dun AR; Norhammar A; Villa G
    Ups J Med Sci; 2022; 127():. PubMed ID: 35722183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Use and Dose of Lipid-Lowering Therapy Post Acute Myocardial Infarction With 5-Year Survival in Older Adults.
    Fayol A; Schiele F; Ferrières J; Puymirat E; Bataille V; Tea V; Chamandi C; Albert F; Lemesle G; Cayla G; Weizman O; Simon T; Danchin N;
    Circ Cardiovasc Qual Outcomes; 2024 May; 17(5):e010685. PubMed ID: 38682335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient characteristics, treatment patterns, and adherence to lipid-lowering therapies following an acute coronary syndrome.
    Bruckert E; Desamericq G; Khachatryan A; Ngo P; Gusto G; Sorio-Vilela F
    Rev Cardiovasc Med; 2020 Dec; 21(4):643-650. PubMed ID: 33388010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid-Lowering Therapy Use and Intensification Among United States Veterans Following Myocardial Infarction or Coronary Revascularization Between 2015 and 2019.
    Zheutlin AR; Derington CG; Herrick JS; Rosenson RS; Poudel B; Safford MM; Brown TM; Jackson EA; Woodward M; Reading S; Orroth K; Exter J; Virani SS; Muntner P; Bress AP
    Circ Cardiovasc Qual Outcomes; 2022 Dec; 15(12):e008861. PubMed ID: 36252093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of a Combined Measure of Adherence and Treatment Intensity With Cardiovascular Outcomes in Patients With Atherosclerosis or Other Cardiovascular Risk Factors Treated With Statins and/or Ezetimibe.
    Khunti K; Danese MD; Kutikova L; Catterick D; Sorio-Vilela F; Gleeson M; Kondapally Seshasai SR; Brownrigg J; Ray KK
    JAMA Netw Open; 2018 Dec; 1(8):e185554. PubMed ID: 30646277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Projected Outcomes of Optimized Statin and Ezetimibe Therapy in US Military Veterans with Coronary Artery Disease.
    Kovach CP; Mesenbring EC; Gupta P; Glorioso TJ; Ho PM; Waldo SW; Schwartz GG
    JAMA Netw Open; 2023 Aug; 6(8):e2329066. PubMed ID: 37638630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry.
    Virani SS; Kennedy KF; Akeroyd JM; Morris PB; Bittner VA; Masoudi FA; Stone NJ; Petersen LA; Ballantyne CM
    Circ Cardiovasc Qual Outcomes; 2018 May; 11(5):e004652. PubMed ID: 29748356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensity of and adherence to lipid-lowering therapy as predictors of goal attainment and major adverse cardiovascular events in primary prevention.
    Mazhar F; Hjemdahl P; Sjölander A; Kahan T; Jernberg T; Carrero JJ
    Am Heart J; 2024 Mar; 269():118-130. PubMed ID: 38109988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Under-representation of ethnic and regional minorities in lipid-lowering randomized clinical trials: a systematic review and meta-analysis.
    Sawant S; Wang N
    Eur J Prev Cardiol; 2023 Aug; 30(11):1120-1131. PubMed ID: 36748994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. More- Versus Less-Intensive Lipid-Lowering Therapy.
    Toyota T; Morimoto T; Yamashita Y; Shiomi H; Kato T; Makiyama T; Nakagawa Y; Saito N; Shizuta S; Ono K; Kimura T
    Circ Cardiovasc Qual Outcomes; 2019 Aug; 12(8):e005460. PubMed ID: 31412729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. European Physician Survey Characterizing the Clinical Pathway and Treatment Patterns of Patients Post-Myocardial Infarction.
    Qureshi N; Antoniou S; Cornel JH; Schiele F; Perrone-Filardi P; Brachmann J; Sidelnikov E; Villa G; Ferguson S; Rowlands C; González-Juanatey JR
    Adv Ther; 2023 Jan; 40(1):233-251. PubMed ID: 36289145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy of intensive lipid-lowering therapies on the reduction of LDLc and of major cardiovascular events.
    Cordero A; Fernández Olmo R; Badimon L; Santos-Gallego CG; Castellano JM; Fácila L; Rodriguez-Manero M; Bonanad C; Vilahur G; Escribano D; Badimon JJ; González-Juanatey JR
    J Clin Lipidol; 2023; 17(5):602-611. PubMed ID: 37775463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid lowering therapy patterns and the risk of cardiovascular events in the 1-year after acute myocardial infarction in United Arab Emirates.
    Pinto L; Farghaly M; Nunna S; Chickballapur Ramachandrachar B; Chilukuri SH; Natarajan A
    PLoS One; 2022; 17(9):e0268709. PubMed ID: 36054205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
    Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ
    JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Model-observational bridging study on the effectiveness of ezetimibe on cardiovascular morbidity and mortality in France: A population-based study.
    Ferrières J; Dallongeville J; Rossignol M; Bénichou J; Caro JJ; Getsios D; Hernandez L; Abenhaim L; Grimaldi-Bensouda L
    J Clin Lipidol; 2016; 10(6):1379-1388. PubMed ID: 27919355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid-lowering treatment intensity, persistence, adherence and goal attainment in patients with coronary heart disease.
    Mazhar F; Hjemdahl P; Clase CM; Johnell K; Jernberg T; Carrero JJ
    Am Heart J; 2022 Sep; 251():78-90. PubMed ID: 35654163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Implications of Switching Lipid Lowering Treatment from Rosuvastatin to Other Agents in Primary Care.
    Colivicchi F; Gulizia MM; Franzini L; Imperoli G; Castello L; Aiello A; Ripellino C; Cataldo N
    Adv Ther; 2016 Nov; 33(11):2049-2058. PubMed ID: 27671328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.